In vivo, it competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. Its main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, thereby playing a role in the prevention and treatment of atherosclerosis and coronary heart disease. It also reduces serum triglyceride levels and increases blood high-density lipoprotein levels.

This product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, thereby playing a role in the prevention and treatment of atherosclerosis and coronary heart disease. This product also reduces serum triglyceride levels and increases blood high-density lipoprotein levels.

Extract from the above information

Olmesartan medoxomil is a prodrug that is absorbed and hydrolyzed into olmesartan through the gastrointestinal tract. Olmesartan is a selective angiotensin II type 1 receptor (AT1) antagonist that blocks the vasoconstrictive effect of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor of vascular smooth muscle. Its action is independent of the ATⅡ synthesis pathway and does not affect bradykinin. Blocking the angiotensin II receptor inhibits the negative feedback regulation mechanism of angiotensin II on renin secretion, but the increase in plasma renin activity and the increase in circulating angiotensin II concentration do not affect the antihypertensive effect of olmesartan.